MannKind Corporation
NASDAQ:MNKD
7.09 (USD) • At close November 4, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | MannKind Corporation |
Symbool | MNKD |
Munteenheid | USD |
Prijs | 7.09 |
Beurswaarde | 1,949,714,550 |
Dividendpercentage | 0% |
52-weken bereik | 3.17 - 7.325 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Michael E. Castagna Pharm.D. |
Website | https://www.mannkindcorp.com |
An error occurred while fetching data.
Over MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)